Aurobindo Pharma gets warning letter from USFDA for Andhra facility

Aurobindo Pharma share price fell as much as 7.7 per cent to Rs 578.75

Aurobindo Pharma has received a warning letter on June 20 from the US Food and Drug Administration (US FDA) for Unit XI, active pharmaceutical ingredient (API) unit in Srikakulam district of Andhra Pradesh.

This is a major adverse regulatory outcome ever faced by the company in recent times. Last month, two of its other API and formulation facilities had received Form 483 with critical observations, which the company said would have no bearing on its business. Stocks fell 3.92 per cent to close at Rs 602.35 on the BSE. During the day, it dropped 7.68 per cent to Rs 578.75. 

The company,